ferences in risk for these subtypes of cardiovascular disease in patients with and without CKD have not been well characterized, which may guide prioritization of targeted therapies to improve the poor prognosis in this high-risk population.
To address these gaps in knowledge, we pooled data from 3 diverse community-based cohorts with considerable representation of African American individuals and older adults and subgroups with a higher burden of CKD as well as cardiovascular disease. We focused on absolute risk differences in CHD, HF, and stroke among patients with CKD vs those without CKD for the purpose of estimating the potential public health benefits that could be achieved through effective prevention and treatment.
Methods
A total of 14 462 participants free of HF, CHD, and stroke from 3 community-based cohorts were pooled in this analysis: the Jackson Heart Study, the Cardiovascular Health Study, and the Multi-Ethnic Study of Atherosclerosis. Each cohort was a multicenter study, and institutional board review approval was obtained at each participating site for each cohort. See the eAppendix in the Supplement for additional details. Chronic kidney disease was defined as estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m 2 calculated from baseline serum creatinine and cystatin C. 7 The outcomes of our study were incident fatal and nonfatal HF, fatal and nonfatal CHD, and fatal and nonfatal stroke. Covariates included demographics, cohorts, hypertension, diabetes, tobacco use, and dyslipidemia. We calculated the unadjusted incidence rates of each primary outcome (incident HF, CHD, and stroke) by CKD status using Poisson regression. We then estimated risk differences, comparing participants with vs without CKD. We evaluated interactions of CKD across strata of age, sex, race/ethnicity, and study cohort. In a sensitivity analysis, we considered urine albumin to creatinine ratio in the definition of CKD. In a second sensitivity analysis, we evaluated incidence rates (IRs) and risk differences across 3 categories of eGFR: greater than 60 mL/min/1.73 m 2 ,45to 59 mL/min/1.73 m 2 and less than 45 mL/min/1.73 m 2 .
Results
Among 14 462 participants, the mean (SD) age was 63 (12) years, 59% (n = 8533) were women, 44% (n = 6363) were African American, and 10% (n = 1461) had CKD (eTable 1 in the Supplement). The mean (SD) time to first HF event was 8.2 (2.5) years, 7.5 (3.1) years to first CHD event, and 7.6 (3.1) years to first stroke event. The unadjusted rates of incident HF, incident CHD, and incident stroke were highest for those with CKD vs without CKD, with HF and CHD having the largest unadjusted risk differences ( Figure 1 ). Unadjusted IRs for participants with and without CKD, respectively, were 22.0 (95% CI, 19.3-24.8) and 6.2 (95% CI, 5.8-6.7) per 1000 person-years for HF; 24.5 (95% CI, 21.6-27.5) and 8.4 (95% CI, 7.9-9.0) per 1000 person-years for CHD; and 13.4 (95% CI, 11.3-15.5) and 4.8 (95% CI, 4.4-5.3) for stroke. The risk differences for HF, CHD, and stroke were attenuated with adjustment; however, all remained statistically significant, with patients with CKD having the greatest absolute risk differences of HF and CHD compared with those without CKD (Table) . Adjusting for demographics, cohort, hypertension, diabetes, hyperlipidemia, and tobacco use, risk differences comparing participants with vs without CKD (per 1000 person-years) were 2.3 (95% CI, 1.2-3.3) for HF, 2.3 (95% CI, 1.2-3.4) for CHD, and 0.8 (95% CI, 0.09-1.5) for stroke. Among subgroups by age, sex, race/ethnicity, and cohort, risks of CHD and stroke events were consistently higher in those with CKD compared with those without CKD ( Figure 2) . Across age and/or sex strata, adjusted risk differences in those with CKD vs without CKD were greatest for HF and CHD. Among African American participants, the risk difference between participants with and without CKD was only statistically significant for HF. Among white participants, risk differences in those 
Key Points
Question How do the absolute rates and risk differences of incident heart failure, coronary heart disease, and stroke differ in participants with and without chronic kidney disease?
Findings This analysis of 3 community-based cohort studies fount that the adjusted risk differences comparing participants with vs without chronic kidney disease (per 1000 person-years) were highest for heart failure and coronary heart disease (and lower for stroke).
Meaning Chronic kidney disease is associated with an excess risk of heart failure that was similar in magnitude to coronary heart disease and greater than stroke.
with vs without CKD were comparable for HF and CHD. The risk difference for HF and CHD in participants with CKD vs participants without CKD was particularly large in Hispanic participants, although there were fewer participants in this subgroup. Among African American and Hispanic participants, adjusted risk differences comparing participants with vs without CKD for HF were 3.5 (95% CI, 1.5-5.5) and 7.8 (95% CI, 2.2-13.3) per 1000 person-years, respectively. In a sensitivity analysis, the adjusted risk difference for HF and CHD was highest for those with both low eGFR and high urine albumin to creatinine ratio (eTable 2 in the Supplement). In a second sensitivity analyses, compared with eGFR greater than 60 mL/min/1.73 m 2 , the adjusted risk differences for incident HF, CHD, and stroke were greatest for participants with eGFR less than 45 mL/min/1.73 m 2 (eTable 3 in the Supplement).
Discussion
In a pooled analysis of 3 diverse community-based cohorts, we compared participants with vs without CKD and found that the absolute risk difference for incident HF was large, comparable with that of incident CHD, and greater than that for stroke. The excess risk of HF associated with CKD was particularly large among African American and Hispanic participants. These results suggest that a focus on prevention and treatment of HF in addition to CHD may improve the overall poor prognosis in patients with CKD. Our findings are consistent with prior reports that have shown that CKD is associated with excess risk of cardiovascular disease.
1,2 Our study augments this body of work by comparing rates of specific cardiovascular disease subtypes in patients with vs without CKD. We evaluated risk in absolute terms, which may translate most directly to the public health benefit that could be derived from effectively preventing or treating a specific subtype of cardiovascular disease.
It has long been recognized that CKD is associated with accelerated coronary atherosclerosis.
8 Cardiovascular prevention and treatment in CKD has largely focused on therapies to decrease risk of CHD, 9 and recent data suggest that development and application of effective medical therapies has reduced the burden of CHD in patients with CKD and patients without CKD. 10, 11 We found that the excess risk of HF among patients with CKD was large and comparable with that of CHD. One possible explanation is that primary prevention therapies for HF remain limited, particularly for preserved ejection fraction HF, which is the most common type of HF in CKD. 12 Second, several novel mechanisms specific to CKD may contribute to the excess risk of HF in patients with CKD including retention of uremic toxins, endothelial dysfunction, inflammation, impaired sodium handling, and deranged mineral metabolism. Thus, identification and modification of novel CKD-specific risk factors for HF may be critical to improving cardiovascular outcomes in this high-risk patient population.
African American and Hispanic participants had the highest incidence rates of HF, CHD, and stroke. Findings from other studies support our data that suggests that African American individuals with CKD are a particularly high-risk subgroup. 13, 14 We also noted that Hispanic patients with CKD had large excess risks of HF and CHD. A 2011 study also found that left ventricular hypertherapy and elevated coronary artery calcification score was more common among Hispanic participants with CKD compared with non-Hispanic participants with CKD.
15
Combined with these earlier studies, our data provide evidence that the excess burden of HF and CHD associated with CKD is particularly great among African American and Hispanic populations.
Strengths and Limitations
Our study had several strengths. We pooled 3 large, community-based patient populations that were diverse in 
eAppendix. Methods

Study populations
The Jackson Heart Study (JHS) is a community-based cohort study of African-Americans designed to evaluate risk factors for cardiovascular disease (CVD). replacement, pacemaker or defibrillator implantation, or any surgery on the heart or arteries, were eligible to participate. For our analysis, we excluded participants who were missing measures of serum creatinine (N=25) or cystatin C (N=40) at baseline or had no follow-up data available (N=5), leaving a final analytic sample of N=6,744 participants.
Chronic Kidney Disease
For all three cohorts, chronic kidney disease (CKD) was defined as estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m 2 . Estimated glomerular filtration rate (eGFR) was calculated from serum concentrations of creatinine and cystatin C measured at baseline (from stored samples) using the 2012 CKD-EPI equation. 6 In JHS, serum creatinine was measured using the Jaffe method and calibrated to measurements traceable to isotope dilution mass spec (IDMS). 7 In CHS, creatinine was measured using a colorimetric method (Ektachem700, Eastman Kodak, Rochester, NY) and also calibrated to Cleveland Clinic. In MESA, serum creatinine was measured by rate reflectance spectrophotometry using thin film adaptation of the creatine amidinohydrolase method on the Vitros analyzer (Johnson & Johnson Clinical Diagnostics) and calibrated to the Cleveland Clinic. In the JHS and in MESA, serum cystatin C was measured by a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Siemens AG, Munich). In CHS, serum cystatin C was measured using a BN II nephelometer (N Latex cystatin C, Dade Behring, Munich, Germany).
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Outcomes
The outcomes of our study were incident fatal and non-fatal heart failure (HF), fatal and non-fatal coronary heart disease (CHD) and fatal and non-fatal stroke. In all three cohorts, cardiovascular events and death were captured by study visits and/or telephone Inpatient stroke was defined by adjudicators after review of medical records for stroke due to brain hemorrhage or infarction. Adjudicators reviewed the medical records, pertinent imaging/procedures and therapies to make a diagnosis of stroke. Stroke was defined as either definite or probable and for this analysis, and both of which were included in this analysis.
Covariates
Demographic characteristics (age, sex and race) were determined by self-report.
Hypertension was defined by use of blood pressure medications or blood pressure >140/90 mmHg. Hyperlipidemia was defined as LDL cholesterol > 160 mg/dL or use of lipid lowering medications. Diabetes was defined as fasting glucose >126 mg/dl or use of oral hypoglycemic medications or insulin. Information on tobacco use was collected from self-report (never, former or current). Physical examination measures and laboratory values were obtained at the baseline study visit. Medication use was determined by medication inventory and was recorded by study personnel.
Statistical methods
We pooled participants from JHS, CHS and MESA for analysis on the individual participant level.
We calculated the unadjusted incidence rates (per 1000 person-years, with 95% confidence intervals) of each primary outcome (incident HF, CHD and stroke) by CKD status (eGFR <60 vs. >60 ml/min/1.73 m 2 ) using Poisson regression. Follow-up time was censored after the first occurrence of the event of interest, death not attributable to the event of interest, loss to follow-up, or the end of follow-up (maximum 6 years after baseline for JHS, truncated at 10 years after baseline for CHS and MESA). We then estimated risk differences, comparing participants with versus without CKD, from the Poisson regression and used a bootstrap analysis of 1000 samples to generate a 95% confidence interval for the risk differences.
We adjusted for (1) demographic factors and cohort, and (2) demographic factors, cohort and CVD risk factors. The CVD risk factors we adjusted for included: age (continuous), sex, race/ethnicity, hypertension (dichotomous), diabetes (dichotomous), tobacco use (dichotomous), and dyslipidemia (dichotomous).
Prior to analyses, we decided to evaluate interactions of CKD with covariates for which we anticipated the absolute rate of CVD events may vary substantially: age (>= 65 or <65 years), gender, race/ethnicity, and study cohort. We adjusted for age as a linear term within each age stratum.
